Company news: Janssen, Zeno Group

Share this article:
Janssen is reassuming ex-US marketing rights for its Caeylx/Doxil cancer treatment. Merck & Co. has marketed the drug abroad since 1996. That deal expires at the end of the year, and marketing rights for the drug will revert to Janssen subsidiary ALZA Corp. Janssen currently markets the product in the US, Japan and Israel under the Doxil brand.

Zeno Group named former Burson-Marsteller healthcare head Ame Wadler managing director for health and strategic planning. Wadler joins the firm from MWW Group, where she was EVP, chief management officer. Before that, she was chief strategic officer at Burson and chairman of the global healthcare practice, having joined that firm from Zeno Group parent Edelman.
Share this article:

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.